Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Dolutegravir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C; HIV infections
- Focus Pharmacokinetics
- 21 Nov 2016 Status changed from recruiting to completed.
- 03 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 03 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.